Demographic, hemodynamic characteristics, and therapeutic trends of pulmonary hypertension patients: The Pulmonary Hypertension Mexican registry (REMEHIP).

Autor: Jerjes-Sánchez C; Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud Monterrey Nuevo Leon Mexico.; Instituto de Cardiología y Medicina Vascular, TecSalud San Pedro Garza Garcia Nuevo Leon Mexico., Ramírez-Rivera A; Unidad de Investigación Clínica en Medicina S.C. Monterrey Nuevo Leon Mexico., Hernandez NZ; Instituto Nacional de Cardiología Ignacio Chavez Mexico City Mexico., Cueto Robledo G; Hospital General de México Mexico City Mexico., García-Aguilar H; Centro Médico Nacional 20 de noviembre, ISSSTE Mexico City Mexico., Gutiérrez-Fajardo P; Cardiotest, Laboratorio de Ecocardiografía Guadalajara Jalisco Mexico., Seoane García de León M; Centro Médico ABC Mexico City Mexico., Moreno Hoyos-Abril F; Hospital Universitario 'Dr. José E. González' UANL Monterrey Nuevo Leon Mexico., Ernesto Beltrán Gámez M; Hospital Angeles de Tijuana Tijuana Baja California Mexico., Elizalde J; Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán Mexico City Mexico., Fccp TP; Instituto Nacional de Cardiología Ignacio Chavez Mexico City Mexico., Sandoval J; Centro Médico ABC Mexico City Mexico.
Jazyk: angličtina
Zdroj: Pulmonary circulation [Pulm Circ] 2024 Jun 17; Vol. 14 (2), pp. e12395. Date of Electronic Publication: 2024 Jun 17 (Print Publication: 2024).
DOI: 10.1002/pul2.12395
Abstrakt: Data on demographic characteristics and therapeutic approaches in Latin American pulmonary arterial hypertension (PAH) patients are scarce. Pulmonary Hypertension Mexican registry (REMEHIP) is a multicenter Mexican registry of adult and pediatric patients, including prevalent and incident cases. Objective: assess clinical characteristics, treatment trends, and in-hospital outcomes. Inclusion: age >2 years, diagnosis of pulmonary hypertension (PH) (groups 1 and 4), right heart catheterization with mPAP ≥25 mmHg, PWP ≤ 15 mmHg, and PVR > 3 Wood unit (WU). We included 875 PH patients, 619 adults, 133 pediatric idiopathic PAH (IPAH), and 123 chronic thromboembolic pulmonary hypertension (CTEPH) patients. We enrolled 48.4% of the incident and 51.6% of the prevalent adult and pediatric patients. PAH adults: age 43 ± 15, females 81.9%, functional class (FC) (I/II) 66.5%, 6-min walk distance (6MWD) 378 ± 112 m, mPAP 57.3 ± 19.0 mmHg, confidence interval (CI) 3.3 ± 1.5 L/min/m 2 , PVR 12.0 ± 8.1 WU. PAH pediatrics: age 9 ± 5, females 51.1%, FC (I/II) 85.5%, 6MWD 376 ± 103 m, mPAP 49.7 ± 13.4 mmHg, CI 2.6 ± 0.9 L/min/m 2 , PVR 16.4 ± 13.5 WU. CTEPH: age 44 ± 17, females 56.1%, FC (I/II) 65.5%, 6MWD 369 ± 126 m, mPAP 49.7 ± 13.4 mmHg, CI 2.6 ± 0.9 L/min/m 2 , PVR 10.5 + 6.5 WU. When we analyzed the IPAH group separately, it sustained a high functional class I/II incidence. REMEHIP shows better functional class in young females with severe PAH than in American and European patients. Also, PAH pediatric patients had a better functional class than other registries. However, our registry also shows that our population's access to specific pharmacologic treatments is still far from optimal.
Competing Interests: The authors declare no conflict of interest.
(© 2024 The Author(s). Pulmonary Circulation published by John Wiley & Sons Ltd on behalf of Pulmonary Vascular Research Institute.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje